Aardvark Therapeutics, Inc. Common Stock (AARD)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 40
- Market Cap
- $108M
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Aardvark Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.